Guardion Health Sciences, Inc. (NasdaqCM:GHSI) has retained Alantra, LLC (‘Alantra') as its financial advisor to assist with the strategic review and transaction process. Robert N. Weingarten, the Chairman of the Board of Directors of Guardion, stated, ‘We do not believe that the current market valuation of the Company accurately reflects the potential value of the Company and our clinical nutrition platform and brand. As fiduciaries on behalf our stockholders, the Guardion Board of Directors has been aggressively exploring a diverse range of strategic options over the past several months to enhance stockholder value.

Our near-term objective is to identify and analyze strategic transactional opportunities, including a sale of the Company and/or its Viactiv® brand, that would be expected to deliver enhanced value to stockholders. In this regard, we have engaged with Alantra, which has demonstrated a substantial record of experience and success in achieving significant results for clients in the Company's industry, and we are looking forward to working with the Alantra team to achieve our objectives'. Bret Scholtes, Guardion's President and Chief Executive Officer, commented, ‘While we are pleased with the progress that we have made since we acquired the Viactiv® brand in June 2021, given current market conditions and realities, we recognize the need to consider other strategic measures, transactions or partnerships that will provide us with the means to better employ and leverage our existing resources and develop new commercial avenues to generate improved returns for our stockholders.

We look forward to partnering with Alantra to help identify and actualize these possibilities'. The Board of Directors has not set a timetable for the strategic review process, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurances that this process will result in a transaction, or that if a transaction is completed, that it will ultimately enhance stockholder value.

The Company does not intend to provide periodic updates until the Board of Directors determines that disclosure is appropriate and/or necessary under the circumstances.